Gene One Life Science Defers Convertible Bond Repayment Until After Capital Raise

• Gene One Life Science corrected its convertible bond repurchase schedule, deferring the KRW 2.6 billion payment previously scheduled for November 4, 2026.
• Early redemption claims will begin following completion of payment for the capital increase.
• Claims totaling KRW 1.56 billion can begin November 27, 2026; another KRW 1.04 billion can be claimed from December 1, 2026.
• The repurchase covers KRW 2.5 billion in bond principal, with the acquired convertible bonds earmarked for resale to fund operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gene One Life Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104000387), on November 04, 2026, and is solely responsible for the information contained therein.